AR126610A1 - Actividad biológica multidimensional optimizada de poli-iclc con tamaño y formulación de componentes controlados - Google Patents
Actividad biológica multidimensional optimizada de poli-iclc con tamaño y formulación de componentes controladosInfo
- Publication number
- AR126610A1 AR126610A1 ARP220102025A ARP220102025A AR126610A1 AR 126610 A1 AR126610 A1 AR 126610A1 AR P220102025 A ARP220102025 A AR P220102025A AR P220102025 A ARP220102025 A AR P220102025A AR 126610 A1 AR126610 A1 AR 126610A1
- Authority
- AR
- Argentina
- Prior art keywords
- poly
- iclc
- formulation
- biological activity
- component size
- Prior art date
Links
- 239000012648 POLY-ICLC Substances 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 229940115270 poly iclc Drugs 0.000 title abstract 4
- 230000004071 biological effect Effects 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 108700002563 poly ICLC Proteins 0.000 abstract 3
- 208000025721 COVID-19 Diseases 0.000 abstract 2
- 208000037847 SARS-CoV-2-infection Diseases 0.000 abstract 2
- 208000036142 Viral infection Diseases 0.000 abstract 2
- 238000011321 prophylaxis Methods 0.000 abstract 2
- 230000009385 viral infection Effects 0.000 abstract 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 abstract 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract 1
- 101001082073 Homo sapiens Interferon-induced helicase C domain-containing protein 1 Proteins 0.000 abstract 1
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 abstract 1
- 102100027353 Interferon-induced helicase C domain-containing protein 1 Human genes 0.000 abstract 1
- 102100024324 Toll-like receptor 3 Human genes 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 230000002255 enzymatic effect Effects 0.000 abstract 1
- 230000002519 immonomodulatory effect Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000000813 microbial effect Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 239000012646 vaccine adjuvant Substances 0.000 abstract 1
- 229940124931 vaccine adjuvant Drugs 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Reivindicación 1: Una molécula Poli-ICLC que comprende un componente Poli-I que tiene una longitud de aproximadamente 0,4 a 5 kilobases y un componente Poli-C que tiene una longitud de aproximadamente 2 a 8 kilobases. Reivindicación 5: La molécula de Poli-ICLC de las reivindicaciones de 1 a 3, o composición de las reivindicaciones 4, para uso en la profilaxis, profilaxis previa a la exposición, tratamiento y/o atenuación de síntomas inflamatorios de infecciones virales o microbianas. Reivindicación 6: La composición Poli-ICLC de la reivindicación 4, en donde la composición tiene efectos inmunomoduladores, adyuvantes de vacunas, antivirales y/o antiinflamatorios mediados por la activación de MDA5, TLR3 y otros sistemas enzimáticos dependientes de dsRNA. Reivindicación 17: Uso, según cualquiera de las reivindicaciones 10 u 11, en donde la infección viral es una infección por SARS-CoV-2. Reivindicación 18: Uso, según cualquiera de las reivindicaciones 10 u 11, en donde la infección viral es una infección por SARS-CoV-2.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163259660P | 2021-07-30 | 2021-07-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR126610A1 true AR126610A1 (es) | 2023-10-25 |
Family
ID=85088227
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220102025A AR126610A1 (es) | 2021-07-30 | 2022-07-29 | Actividad biológica multidimensional optimizada de poli-iclc con tamaño y formulación de componentes controlados |
Country Status (2)
| Country | Link |
|---|---|
| AR (1) | AR126610A1 (es) |
| WO (1) | WO2023009171A2 (es) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7439349B2 (en) * | 2002-07-03 | 2008-10-21 | Andres Salazar | Method for preparation of large volume batches of poly-ICLC with increased biological potency; therapeutic, clinical and veterinary uses thereof |
| EP3082853A2 (en) * | 2013-12-20 | 2016-10-26 | The Broad Institute, Inc. | Combination therapy with neoantigen vaccine |
| JP2020520368A (ja) * | 2017-05-17 | 2020-07-09 | ビオンコテック セラピューティクス エセ．エレ | 二本鎖ポリリボヌクレオチドとポリアルキレンイミンとの複合体を含む粒子を含む新規な医薬組成物 |
-
2022
- 2022-07-29 AR ARP220102025A patent/AR126610A1/es unknown
- 2022-08-04 WO PCT/US2022/000015 patent/WO2023009171A2/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023009171A3 (en) | 2023-05-11 |
| WO2023009171A2 (en) | 2023-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022018819A2 (pt) | Vacinas contra coronavírus e métodos de uso | |
| BR112022017308A2 (pt) | Composição que compreende lactoferrina e cepas bacterianas probióticas para uso oral com ação antiviral | |
| CL2016000240A1 (es) | Composición inmunogénica de reovirus de peces (prv) que comprende ácido nucleico del prv; polipéptido; virus atenuado o inactivado del prv, uso de la composición inmunogénica que sirve para tratar afecciones de infeción por prv en un animal. | |
| CL2023001949A1 (es) | Anticuerpos que se dirigen al gp120 de vih y métodos de uso (divisional de solicitud de patente no. 3422-2020) | |
| BR112016026556A8 (pt) | inibidores de mek, de p38 e/ou de nfkb, seus usos, composição, sistema de teste in vitro, seu uso, e método para detecção de moléculas eficazes na profilaxia e/ou tratamento de uma co-infecção | |
| BRPI0720569B8 (pt) | compostos de tetraciclina substituída e uso dos ditos compostos para o tratamento de uma infecção bacteriana, viral ou parasitária | |
| AR118734A1 (es) | Formulaciones y métodos de vectores de virus adenoasociados | |
| CL2015003120A1 (es) | Cepas bacterianas que poseen actividad antimicrobiana y composiciones de control biológico que las contienen | |
| AR030068A1 (es) | Composiciones farmaceuticas para el tratamiento de condiciones dolorosas, inflamatorias y ulcerosas de superficies epiteliales humedas como por ejemplo mucositis, estomatitis y sindrome de behcet | |
| BR112018014794A2 (pt) | pirimidinas substituídas com arila para uso em infecção pelo vírus influenza | |
| BR112023002951A2 (pt) | Compostos de fosfolipídio e usos destes | |
| MX2020003473A (es) | Nuevo inhibidor de proteina-cinasa-cinasa activada por mitogeno (mek) para el tratamiento de infecciones virales y bacterianas. | |
| BR112023001129A2 (pt) | Pró-fármacos antivirais, formulações farmacêuticas e métodos | |
| BR112022002123A2 (pt) | Composição farmacêutica para produzir uma quantidade segura de óxido nítrico e seu uso | |
| MX2022010542A (es) | Composiciones y metodos para reducir la expresion de citocinas. | |
| BR112022000957A2 (pt) | Uso de progestógeno para inibir tempestade de citocina e composição compreendendo progestógeno | |
| AR126610A1 (es) | Actividad biológica multidimensional optimizada de poli-iclc con tamaño y formulación de componentes controlados | |
| BR112022021423A2 (pt) | Uso de proteína surfactante d para tratar infecções virais | |
| CL2022002239A1 (es) | Tafoxiparina para el tratamiento de la preeclampsia | |
| UY39313A (es) | Composiciones amortiguadoras para el tratamiento de infecciones virales transmitidas por el aire | |
| CO2024004598A2 (es) | Moléculas de arn | |
| AR106057A1 (es) | Composición con efecto antiviral, composición farmacéutica | |
| BR112021020605A2 (pt) | Inibidor de mek para o tratamento de infecções virais e bacterianas | |
| BR112017019534A2 (pt) | substrato fibroso para captura de bacterias gram-negativas | |
| BR112021022806A2 (pt) | Método para tratar a infecção crônica por hbv, sirna, usos de um sirna, e de um sirna e peg-ifna e de um sirna, peg-ifna e um nrti, método, composição para uso ou uso e kit |